---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-076825"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:52:42.204401+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q2 revenue $15.0M; Emrosi sales $2.8M in first full quarter

## Summary
- Net loss of $3.8M ($0.16 EPS) vs $3.4M loss ($0.17 EPS) in Q2 2024.
- Total net product revenue $15.0M, up slightly from $14.9M year-over-year.
- Gross margin improved to 67% from 61% due to favorable product mix and lower COGS.
- SG&A expenses rose to $11.9M from $10.3M, driven by Emrosi launch costs.
- Adjusted EBITDA loss of $0.5M vs positive $0.3M in prior year period.

## SEC filing metadata
- accession: 0001104659-25-076825
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465925076825/0001104659-25-076825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465925076825/tm2523268d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-076825
- JSON: https://secwatch.observer/filing/0001104659-25-076825.json
- Plain text: https://secwatch.observer/filing/0001104659-25-076825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.